来源：智通财经 图 2:春季~两会,A股上涨明显;港股没有明显的目历效应 E SECTION FOR ■ 上涨概率:春节->两会(2010年~2015年 100% 93.8% -93.8% 93.8% 87.5% 90% 81.39 it 80% 72.7% 184 2 5: 70% 62.5% 62.5% 56.3% 54 .! 60% 50% 40% 30% 20% 10% 0% el ch 02肖 717 班 极 数据来源：Wind,广发证券发展研究中心。备注：恒生科技、恒生港股通、港股通高股息采用 2016~2 图 3: 过去15年,春节后港股各指数日历效应 | 上涨概率 | 圣诞节-春节前 | 春节后-两会 | 两会期间 | 两会-3月底 | 1月 | | --- | --- | --- | --- | --- | --- | | 恒生科技 | 72.7% | 72.7% | 45.5% | 50.0% | 63.6% | | 恒生指数 | 80.0% | 46.7% | 40.0% | 42.9% | 73.3% | | 恒生中国企业指数 | 73.3% | 40.0% | 46.7% | 57. ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The pharmaceutical index in A-shares has shown a slight increase of 0.14% this week and 3.28% year-to-date, outperforming the CSI 300 by 1.41% and 0.85% respectively [3][8] - The report highlights the emergence of molecular glue as a significant trend in the industry, with several successful stocks like RVMD, GLU, and KYMR, and substantial business development (BD) activities [3][15] - The report suggests that molecular glue has the potential to create new blockbuster drugs in oncology and autoimmune diseases, urging investors to focus on domestic companies involved in this area [3][11] Summary by Sections 1. Market Performance - The A-share pharmaceutical index has outperformed the CSI 300 index, with notable gains in traditional Chinese medicine (2.56%), medical services (1.31%), and raw materials (0.64%) [3][8] - The report lists top-performing stocks, including Guangsheng Tang (+29.83%) and HaiXiang Pharmaceutical (+18.64%), while noting declines in stocks like Changshan Pharmaceutical (-15.78%) [8] 2. Molecular Glue - Molecular glue is defined as a class of small molecule drugs that facilitate the binding of E3 ubiquitin ligases to previously unrecognized pathogenic target proteins, leading to their degradation [15] - The report mentions that BMS has two marketed molecular glues with peak sales exceeding $16 billion, and ongoing research into new iterations [3][15] - Domestic companies such as Yuan Dong Biology and Jin Fang Pharmaceutical are noted for their potential in molecular glue development [3][11] 3. R&D Progress and Corporate Developments - The report highlights significant clinical research milestones, including Pfizer's initiation of a Phase II/III trial for its PD-1/VEGF bispecific antibody SSGJ-707 [3] - It also notes that Novartis has submitted its BAFF-R monoclonal antibody for approval in China, and AbbVie has started a Phase II trial for its Bcl-2 inhibitor Venetoclax [3] 4. Recommended Stocks - The report provides a list of recommended stocks across various sectors, including: - CXO and upstream research services: WuXi AppTec, Hao Yuan Pharmaceutical, and Aopumai [11] - Traditional Chinese medicine: Zuo Li Pharmaceutical and Fang Sheng Pharmaceutical [11] - PD-1 PLUS: 3SBio, KANGFANG Biologics, and Innovent Biologics [11] - ADC: Ying En Biologics and Kelong Biotechnology [11] - AI drug development: Jing Tai Holdings [11]

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 分子胶海外风起，国内管线蓄势破局 2026 年 02 月 09 日 增持（维持） [Table_Tag] [Table_Summary] 投资要点 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -8% -4% 0% 4% 8% 12% 16% 20% 24% 2025/2/10 2025/6/10 2025/10/8 2026/2/5 医药生物 沪深300 相关研究 《降息等多因素支持科研上游持续复 苏，重点推荐皓元医药、奥浦迈等》 2026-02-01 《mRNA 疫苗龙头释放积极临床数据 信号，建议关注悦康药业、康希诺等》 2026-01-26 东吴证券研究所 1 / 45 请务必阅读正文之后的免责声明部分 ◼ 本周、年初至今 A 股医药指数涨幅分别为 0.14%、3.28%，相对沪深 300 的超额收益分别为 1.41%、0.85%；本周、年初至今恒生生物科技指数涨 跌幅分别为-1.31%、7.34%，相对于恒生科技指数跑赢 5.20%、10.41%； 本周中药（2.56%）、医疗服务 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The supply of raw materials in the pharmaceutical industry is accelerating, with a focus on subsequent price and volume changes [2] - The global GLP-1 market is evolving, with Chinese companies continuing to explore international opportunities [3] - Leading companies are gradually entering the small nucleic acid field, which is expected to drive the development of supporting industrial chains [4] - The retail pharmaceutical market is showing positive trends, with chain pharmacies enhancing their positioning [5] - The value of oral immunosuppressive drugs is gaining attention [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 1.47 percentage points in the last week, ranking 15th among 31 primary industry indices [18] - The pharmaceutical industry index increased by 0.14% during the same period [18] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has a current PE (TTM) of 37.31, above the five-year historical average of 31.11 [40] 3. Recent Research Achievements - The report highlights various deep-dive studies on topics such as the growth of biological agents and oral medications, and the impact of policies on the inhalation drug industry [44] 4. Recent Industry Policies and News - The National Healthcare Security Administration issued a notice to accelerate the cultivation and application of new scenarios in the medical insurance sector [46] - Recent approvals for clinical trials of new drugs by major pharmaceutical companies, including AstraZeneca and Hengrui Medicine, indicate ongoing innovation in the industry [47][48] 5. Key Companies and Profit Forecasts - The report includes profit forecasts for several companies, with recommendations for stocks such as Yuyuan Pharmaceutical and Sunshine Nuohua, indicating a positive outlook for their performance [9]

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].

Group 1 - In 2025, China's GDP is projected to exceed 140 trillion yuan, marking a significant milestone in economic development and indicating a systemic transition in growth logic, structural dynamics, and value coordinates [1] - The concept of "Duxing" (笃行) is highlighted as a core strength driving China's economic resilience and high-quality development, rooted in new productive forces [1] - Key advancements in hard technology are expected, with companies like Cambrian achieving profitability in AI chips, Blue Arrow Aerospace completing critical launches, and Huawei establishing a self-controlled technology ecosystem [1] Group 2 - The integration of digital technology with the real economy is entering a deeper phase, with Alibaba leveraging AI in retail and logistics, Industrial Fulian transforming manufacturing processes, and Heng Rui Pharmaceutical focusing on innovative drug development [2] - The domestic capital market is shifting towards value investment, with patient capital flowing into hard technology, green industries, and specialized enterprises, while the global market sees Chinese exports in new energy vehicles and lithium batteries leading due to technological and quality advantages [3] - The year 2025 is positioned as a pivotal moment for China's economic trajectory, setting a solid foundation for the 14th Five-Year Plan's conclusion and the 15th Five-Year Plan's commencement [3]

Market Overview - The Hong Kong stock market opened higher on February 9, with the Hang Seng Index rising by 1.59% to 26,982.49 points, the Hang Seng Tech Index up by 1.9% to 5,447.63 points, and the National Enterprises Index increasing by 1.54% to 9,170.57 points. The Red Chip Index rose by 0.89% to 4,399.55 points [1] - Last week, the Hang Seng Index recorded a significant decline of 3.02%, while the National Enterprises Index fell by 3.07%, and the Hang Seng Tech Index dropped by 6.51% [1] Company Performance and Dynamics - Beijing Capital International Airport Co. (00694.HK) issued a profit warning, expecting a net loss of 600 million to 760 million yuan for 2025, which represents a year-on-year reduction in losses of approximately 45.3% to 56.8%. This improvement is attributed to the recovery in aviation market demand and enhanced cost control [2] - Times Electric (03898.HK) reported preliminary results indicating total revenue of approximately 28.761 billion yuan for 2025, a year-on-year increase of 15.46%, with a net profit of about 4.105 billion yuan, up by 10.88% [2] - Power sector stocks saw a general increase, with Datang Environment (01272.HK) expecting a pre-tax profit of 700 million to 710 million yuan for 2025. Datang New Energy (01798.HK) reported a power generation of 3.272 million MWh in January, a year-on-year increase of 6.69%, while Longyuan Power (00916.HK) generated 7.1627 million MWh, up by 12.05%, with solar power generation increasing by 42.25% [2] Real Estate Sales - Yuexiu Property (00123.HK) reported a contract sales amount of 4.201 billion yuan in January, a year-on-year decrease of 36.4%. Poly Real Estate (01238.HK) had sales of 470 million yuan, down by 31.98%. In contrast, Greenland Hong Kong (00337.HK) saw a significant increase in sales to 508 million yuan, up by 287.79% year-on-year [3] Pharmaceutical and Technology Developments - CloudTop New Medicine (01952) received approval for a new drug application for the treatment of ulcerative colitis. Kelun-Biotech (06990.HK) received approval for the fourth indication of its core product TROP2 ADC. Heng Rui Medicine (01276.HK) had its HRS-4642 injection included in the breakthrough therapy list [4] - ZTE Corporation (00763.HK) plans to invest 200 million yuan to subscribe to shares of the Guangdong-Hong Kong-Macao fund, focusing on hard technology sectors [4] Stock Buybacks and Financing - Kingsoft (03888.HK) repurchased 1.1142 million shares for approximately 29.9994 million HKD. Geely Automobile (00175.HK) repurchased 166.5 million shares for about 27.1612 million HKD. October Rice Field (09676.HK) repurchased 78 million shares for approximately 7.3357 million HKD. China Galaxy (06881.HK) completed the issuance of 6 billion yuan in corporate bonds [5] Institutional Perspectives - According to浦银国际, the market is expected to maintain a volatile trend in the short term, with a rotation of style. The inflow of incremental funds is slowing before the Spring Festival, and external liquidity is affected by geopolitical uncertainties and Trump’s policies, limiting the expansion space for Hong Kong stock valuations [6] - 广发证券 noted that historical data shows an 82% probability of the Hang Seng Index rising in the three days before the Spring Festival, although there is no significant calendar effect afterward. The current situation differs due to changes in Hong Kong stock pricing logic and increased correlation with A-shares, suggesting a potential passive follow-up increase in Hong Kong stocks [7]

绿通科技：绿通产业基金拟1000万元投资圣昊光电，后者主营光通信（核心股）芯片测试设备 东田微：拟投资4亿元建设全球研发中心及华南制造总部项目，主要从事研发光通信（核心股）精密光 学元器件等 爱旭股份：与Maxeon签订《专利许可协议》 赛力斯：与重庆市沙坪坝区人民政府签署合作协议，以蓝电汽车相关存量资产剥离出资设立标的公司 【重要事项】 沙河股份：拟2.74亿元购买晶华电子70%股份 构成重大资产重组（核心股） 杉杉股份：若重整成功，公司实际控制人将变更为安徽省国资委 永太科技：拟购买永太高新25%股权，宁德时代将成为公司股东 【投资&签约】 中兴通讯：拟出资2亿元认购粤港澳大湾区创业投资引导基金合伙企业份额 【经营】 长盈精密：人形机器人（核心股）精密零组件2025年营收约1亿元，为AI品牌方提供服务器数据传输铜 缆 恒瑞医药（核心股）：HRS-4642注射液纳入突破性治疗品种名单，目前国内外尚无同类药物获批上市 众生药业：控股子公司一类创新药昂拉地韦两项III期临床试验获积极结果 天成自控：子公司武汉天成收到国内头部某汽车企业乘用车座椅定点通知，项目生命周期5年，预计总 金额23亿元 股票频道更多独家策 ...

今日关注 新股上市：澜起科技（06809.HK） 新股申购：通宝光电（920168.BJ） 2026春节档片单发布活动暨中国电影新春嘉年华将于2月9日举行。 首届全球人形机器人自由格斗联赛（URKL）将于2月9日召开启动发布会。 超快化学与人工智能学术研讨会将于2月9日举办。 标普道琼斯指数公司：Ciena将取代Dayforce纳入标普500指数，调整将于2月9日开盘前生效。 芝商所计划于2月9日推出100盎司白银期货合约。 今日有750亿元7天期逆回购到期。 隔夜市场 上周五美国三大股指全线收涨，道指涨2.47%报50115.67点，创历史新高，标普500指数涨1.97%报 6932.3点，纳指涨2.18%报23031.21点。英伟达涨近8%，市值增加3250亿美元，卡特彼勒涨超7%，领涨 道指。纳斯达克中国金龙指数涨3.71%。上周道指累计上涨2.5%，标普500指数跌0.1%，纳指跌1.84%。 上周五国际贵金属期货普遍收涨，COMEX黄金期货涨2.03%报4988.60美元/盎司，周涨5.13%， COMEX白银期货涨1.06%报77.53美元/盎司，周跌1.28%。 美油主力合约收涨0.33%，报6 ...

1、道指历史首次站上5万点！中概股指数涨超3%，白银、比特币集体暴涨 类型：市场 情绪影响：正面 上周五全球资产集体爆发，标普500指数迎来自去年5月以来的最大单日涨幅，道指也历史性地站上了5 万点关口。英伟达单日涨超7%，市值增加超3200亿美元，纳斯达克中国金龙指数大涨3.71%。代表着极 致风险偏好的现货白银周五反弹近10%，比特币也涨近12%。 2、商业航天突传大消息！我国成功发射可重复使用试验航天器 类型：行业 盘前要闻 情绪影响：正面 2月7日，我国在酒泉卫星发射中心使用长征二号F运载火箭，成功发射一型可重复使用试验航天器。试 验航天器将按计划开展可重复使用试验航天器技术验证，为和平利用太空提供技术支撑。有分析指出， 随着2026年我国可重复使用试验航天器技术验证的成功，商业航天有望步入高频发射常态化阶段。 3、国常会研究促进有效投资政策措施，深入谋划实施一批重大举措、重大项目 类型：宏观 情绪影响：正面 上周五晚间国常会提出，促进有效投资对于稳定经济增长、增强发展后劲具有重要作用。在基础设施、 城市更新、公共服务、新兴产业和未来产业等重点领域，深入谋划推动一批重大项目、重大工程。要更 好发挥央国 ...